Literature DB >> 17028114

A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis.

Takahiko Horiuchi1, Chikako Kiyohara, Hiroshi Tsukamoto, Takuya Sawabe, Isao Furugo, Seiji Yoshizawa, Akira Ueda, Yoshifumi Tada, Tadashi Nakamura, Yasutaka Kimoto, Hiroki Mitoma, Shinichi Harashima, Shigeru Yoshizawa, Terufumi Shimoda, Seiich Okamura, Kohei Nagasawa, Mine Harada.   

Abstract

OBJECTIVES: To perform a case-control study of a functional M196R polymorphism of tumour necrosis factor receptor type 2 (TNF-RII) in a Japanese population and a meta-analysis of all published reports on the polymorphism to investigate the association of the M196R polymorphism of TNF-RII with systemic lupus erythematosus (SLE).
METHODS: The functional M196R polymorphism of TNF-RII was genotyped by using polymerase chain reaction combined with the subsequent single-strand conformation polymorphism (PCR-SSCP) analysis for screening, followed by nucleotide sequencing for confirmation. A total of 331 patients and 359 controls were subjected to a case-control study. A meta-analysis of the available case-control studies including all published data as well as our own data was performed to investigate the association of the functional M196R polymorphism of TNF-RII with SLE.
RESULTS: Our case-control study did not show any significant association of a functional M196R polymorphism of TNF-RII with SLE, although there was a trend towards association. A meta-analysis of seven case-control studies in eight different ethnic populations including our own showed that 196M/R and 196R/R genotypes combined was significantly associated with an increased risk of SLE (odds ratio (OR) 1.29, 95% confidence interval (CI) 1.04 to 1.60; p = 0.02). Stratification by ethnicity showed a more significant association in Asians, including Japanese, Korean and Vietnamese (OR 1.40, 95% CI 1.10 to 1.78; p = 0.006). The effect of the 196R allele on SLE was not clear in Caucasians.
CONCLUSIONS: The 196R allele of the functional M196R polymorphism of TNF-RII is a risk factor for SLE, especially in the Asian population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028114      PMCID: PMC1856025          DOI: 10.1136/ard.2006.058917

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  40 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus.

Authors:  M Rudwaleit; M Tikly; M Khamashta; K Gibson; J Klinke; G Hughes; P Wordsworth
Journal:  J Rheumatol       Date:  1996-10       Impact factor: 4.666

3.  Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis.

Authors:  C Morita; T Horiuchi; H Tsukamoto; N Hatta; Y Kikuchi; Y Arinobu; T Otsuka; T Sawabe; S Harashima; K Nagasawa; Y Niho
Journal:  Arthritis Rheum       Date:  2001-12

4.  Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test.

Authors:  N Tsuchiya; A Kawasaki; B P Tsao; T Komata; J M Grossman; K Tokunaga
Journal:  Genes Immun       Date:  2001-10       Impact factor: 2.676

5.  Tumor necrosis factor receptor 2 polymorphism in systemic lupus erythematosus: no association with disease.

Authors:  E B Lee; J E Yoo; Y J Lee; Y J Choi; K S Park; Y W Song
Journal:  Hum Immunol       Date:  2001-10       Impact factor: 2.850

6.  A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families.

Authors:  P M Gaffney; G M Kearns; K B Shark; W A Ortmann; S A Selby; M L Malmgren; K E Rohlf; T C Ockenden; R P Messner; R A King; S S Rich; T W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

7.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10

Review 8.  Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.

Authors:  M Aringer; J S Smolen
Journal:  Lupus       Date:  2004       Impact factor: 2.911

9.  A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha.

Authors:  A G Wilson; C Gordon; F S di Giovine; N de Vries; L B van de Putte; P Emery; G W Duff
Journal:  Eur J Immunol       Date:  1994-01       Impact factor: 5.532

10.  A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.

Authors:  E Douni; G Kollias
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

View more
  13 in total

1.  Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ.

Authors:  Mehdi Anvari; Omid Khalilzadeh; Alireza Esteghamati; Fatemeh Momen-Heravi; Mahdi Mahmoudi; Shadi Abdar Esfahani; Armin Rashidi; Aliakbar Amirzargar
Journal:  Endocrine       Date:  2010-03-05       Impact factor: 3.633

2.  Tumour necrosis factor receptor 2 (TNFRSF1B) association study in Sjögren's syndrome.

Authors:  Corinne Miceli-Richard; Philippe Dieude; Eric Hachulla; Xavier Puechal; François Cornelis; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2007-12       Impact factor: 19.103

3.  Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.

Authors:  I Parodis; H Ding; A Zickert; L Arnaud; A Larsson; E Svenungsson; C Mohan; I Gunnarsson
Journal:  Scand J Rheumatol       Date:  2016-12-15       Impact factor: 3.641

4.  Association of killer cell immunoglobulin-like receptor and human leucocyte antigen-Cw gene combinations with systemic lupus erythematosus.

Authors:  Y Hou; C Zhang; D Xu; H Sun
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Tumor necrosis factor receptor 2 (TNFR2)·interleukin-17 receptor D (IL-17RD) heteromerization reveals a novel mechanism for NF-κB activation.

Authors:  Shigao Yang; Yinyin Wang; Kunrong Mei; Sen Zhang; Xiaojun Sun; Fangli Ren; Sihan Liu; Zi Yang; Xinquan Wang; Zhihai Qin; Zhijie Chang
Journal:  J Biol Chem       Date:  2014-11-05       Impact factor: 5.157

6.  TNFR 2 M196R polymorphism and acne vulgaris in Han Chinese: a case-control study.

Authors:  Liming Tian; Hongfu Xie; Ting Yang; Yaohua Hu; Ji Li; Weizhen Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

Review 7.  Associations between functional TNFR2 196 M/R polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.

Authors:  Gwan Gyu Song; Sang-Cheol Bae; Young Ho Lee
Journal:  Rheumatol Int       Date:  2014-04-29       Impact factor: 2.631

Review 8.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

9.  Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.

Authors:  Chi Chiu Mok; Hui Hua Ding; Marwa Kharboutli; Chandra Mohan
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-07-28       Impact factor: 4.794

10.  TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Authors:  Akiko Kuwahara; Motohiro Yamamori; Megumi Fujita; Tatsuya Okuno; Takao Tamura; Kaori Kadoyama; Noboru Okamura; Tsutomu Nakamura; Toshiyuki Sakaeda
Journal:  J Exp Clin Cancer Res       Date:  2010-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.